Refine
Year of publication
Document Type
- Doctoral Thesis (97) (remove)
Has Fulltext
- yes (97)
Is part of the Bibliography
- no (97)
Keywords
- Heterologe Genexpression (3)
- Endothelin (2)
- G-Protein gekoppelte Rezeptoren (2)
- Gentherapie (2)
- HIV (2)
- Membrane Proteins (2)
- NMR-Spektroskopie (2)
- gene therapy (2)
- 5-Lipoxygenase (1)
- APOBEC3G (1)
- Acute Promyelocytic Leukemia (1)
- AlignMe (1)
- Alignment (1)
- Aminosäurensequenz (1)
- Angeborene Immunität (1)
- Angiogenese (1)
- Arzneimitteldesign (1)
- B-cell lymphoma (1)
- Biacore (1)
- Biochemie (1)
- Biophysik (1)
- Blutgefäßsystem (1)
- Breast Cancer (1)
- Brustkrebs (1)
- C peptide (1)
- C-Peptid (1)
- CD34+ Zellen (1)
- CD34+ cells (1)
- Cell-free Protein Expression (1)
- Cell-free Protein Synthesis (1)
- Cell-free protein synthesis (1)
- Chromatin (1)
- Corynebakterium efficiens (1)
- Crystallography (1)
- DNA Methylation (1)
- DNA-Methylierung (1)
- Detergenz (1)
- Deubiquitination (1)
- Diffuse large B-cell lymphoma (1)
- Docking (1)
- Drug Design (1)
- EGFR vIII (1)
- Eintrittsinhibitor (1)
- Einzelmolekülanalyse (1)
- Electron Paramagnetic Resonance (1)
- Endothelin B Rezeptor (1)
- Endothelin Receptor B (1)
- Endothelin-Rezeptor (1)
- Endothelzelle (1)
- Epidermal growth factor receptor (1)
- Ferroptosis (1)
- Fettsäuresynthase Typ I (1)
- G-protein coupled receptor (1)
- GPCR (1)
- Genregulation (1)
- HIV-Infektion (1)
- Histon-Deacetylierung (1)
- Histone Deacetylation (1)
- IGF-1R (1)
- Immunkomplex (1)
- Integrale Membranproteine (1)
- Interferon <alpha-> (1)
- Interferon response (1)
- Kristallkeimbildung (1)
- Kristallografie (1)
- Lentivirale Vektoren (1)
- Ligand <Biochemie> (1)
- Lipid Environment (1)
- Lipopolysaccharide (1)
- Lysozym (1)
- Magnetische Kernresonanz (1)
- Massenspektrometrie (1)
- Mehrdimensionale NMR-Spektroskopie (1)
- Membrane Protein Alignments (1)
- Membranproteine (1)
- Mitochondrial protein import (1)
- Mitophagy (1)
- Molekulare Maschinerien (1)
- Monoklonaler Antikörper (1)
- Monozyt (1)
- Multi-domain proteins (1)
- Multikatalytische Proteasen (1)
- Mutagenese (1)
- N-glycoproteome (1)
- NMR spectroscopy (1)
- NMR-Spectroscopy (1)
- Nanodiscs (1)
- PAM-complex (1)
- PELDOR / DEER (1)
- Phosphoproteome (1)
- Polypeptid transport-associated domains (1)
- Preseniline (1)
- Promoter (1)
- Promotor (1)
- Proteasome inhibitor (1)
- Proteindegradation (1)
- Proteinexpression (1)
- Proteinfaltung (1)
- Proteinregulation (1)
- Proteolyse (1)
- Pulmonale Hypertonie (1)
- Radioliganden (1)
- Rezeptor-Tyrosinkinasen (1)
- Röntgenkristallographie (1)
- SUMOylation (1)
- Sekretion (1)
- Selbstkompartimentierung (1)
- Septische Granulomatose (1)
- Smac mimetic (1)
- Sp1 (1)
- Sumoylation (1)
- Sumoylierung (1)
- Transcriptional activity (1)
- Transkriptionsfaktor (1)
- Trichostatin A (1)
- Tumorsuppressor-Gen (1)
- Ubiquitin (1)
- Ubiquitin chains (1)
- Ubiquitinome (1)
- Wirkstoff-Rezeptor-Bindung (1)
- Zellfreies System (1)
- acyl carrier protein, polyketide synthases, Curacin cluster (1)
- amyloidogenesis (1)
- cell-free (1)
- detergent (1)
- dynamics (1)
- endothelial cell (1)
- endothelin receptor (1)
- entry inhibitor (1)
- free mRNA (1)
- functional (1)
- glatte Gefäßmuskelzellen (1)
- hen egg white lysozyme (1)
- integral membrane proteins (1)
- lentiviral vector (1)
- ligand (1)
- membrane protein complexes (1)
- miRNS (1)
- microRNA (1)
- microRNA-17-92 cluster (1)
- monocytes (1)
- nicht-native Proteine (1)
- non-native proteins (1)
- p63 (1)
- potassium transporter (1)
- preparative cell-free expression (1)
- protein expression (1)
- protein folding (1)
- proteostasis stress (1)
- pulmonary hypertension (1)
- radioligand (1)
- respiratory chain (1)
- secretion (1)
- single particle cryo-EM (1)
- smooth muscle cell (1)
- solution-state NMR (1)
- supercomplex (1)
- voltage-gated proton channels (1)
- voltage-sensing domains (1)
- voltage-sensing phosphatases (1)
- xCGD (1)
- zellfrei (1)
- zellfreie Expression (1)
Institute
- Biochemie und Chemie (63)
- Biochemie, Chemie und Pharmazie (30)
- Pharmazie (5)
- Biowissenschaften (1)
- Georg-Speyer-Haus (1)
Die Fähigkeit der spezifischen und kontextabhängigen zellulären Adaption auf intrinsische und/oder extrinsische Signale ist das Fundament zellulärer Homöostase. Verschiedene Signale werden von Membranrezeptoren oder intrazellulären Rezeptoren erkannt und ermöglichen die molekulare Anpassung zellulärer Prozesse. Komplexe, ineinandergreifende Proteinnetzwerke sind dabei elementar in der Regulation der Zelle. Proteine und deren Funktionen werden dabei nach Bedarf reguliert und unterliegen einem ständigen proteolytischen Umsatz.
Die stimulusabhängige Gentranskription und/oder Proteintranslation nimmt hier eine zentrale Stellung ein, da die zugrundeliegende Maschinerie die Komposition und Funktion der Proteinnetzwerke entsprechend anpassen kann. Zusätzlich zur Regulation der Proteinabundanz werden Proteine posttranslational modifiziert, um deren Eigenschaften rasch zu ändern. Zu posttranslationalen Modifikationen zählen die Ubiquitinierung und/oder Phosphorylierung, welche die Proteinfunktionen hochdynamisch regulieren. Deregulierte Proteinnetzwerke werden oft mit Neurodegeneration und Autoimmun- oder Krebserkrankungen assoziiert. Auch Infektionen mit humanpathogenen Bakterien greifen stark in den Regulierungsprozess von Proteinnetzwerken und deren Funktionen ein. Die zelluläre Homöostase wird dadurch herausgefordert.
Bakterien der Gattung Salmonella sind zoonotische, gramnegative, fakultativ intrazelluläre Pathogene, welche weltweit millionenfach Salmonellen-erkrankungen hervorrufen. Von besonderer Bedeutung ist dabei Salmonella enterica serovar Typhimurium (hiernach Salmonella), welches im Menschen, meist durch mangelnde Hygienemaßnahmen, Gastroenteritis auslöst.
Immunität in Epithelzellen wird über das angeborene Immunsystem vermittelt und dient der Pathogenerkennung und -bekämpfung. Die Toll-like Rezeptoren (TLR) gehören zu den Mustererkennungsrezeptoren (pattern recognition receptors), welche spezifische mikrobielle Strukturen detektieren und eine kontextabhängige zelluläre Antwort generieren. Danger-Rezeptoren erkennen hingegen nicht direkt das Pathogen, sondern zelluläre Perturbationen, welche durch Zellschäden oder bakterielle Invasionen verursacht werden. Die intrinsische Fähigkeit der Wirtszelle, sich gegen Infektionen/Gefahren zu wehren wird dabei als zellautonome Immunität bezeichnet. Dabei nehmen induzierte proinflammatorische Signalwege und zelluläre Stressantworten eine wichtige Stellung ein. Die zelluläre Stressantwort aktiviert unter anderem die selektive Autophagie. Diese kann spezifisch aberrante Organelle, Proteine und invasive Pathogene abbauen. Ein weiterer Stresssignalweg ist die integrated stress response (ISR), welche eine selektive Proteintranslation erlaubt und damit die Auflösung des proteintoxischen Stresses ermöglicht.
Zur Penetration von Epithelzellen benötigt Salmonella ein komplexes System an Virulenzfaktoren, welches die bakterielle Internalisierung und Proliferation in der Wirtszelle ermöglicht. Salmonella nutzt dazu ein Typ-III-Sekretionssystem. Das System sekretiert bakterielle Virulenzfaktoren in die Zelle, sodass eine hochspezifische Modulierung des Wirtes erzwungen wird.
Die Virulenzfaktoren SopE und SopE2 spielen dabei eine Schlüsselrolle, da sie die Pathogenität von Salmonella maßgeblich vermitteln. Durch molekulare Mimikry von Wirts GTP (Guanosintriphosphat) -Austauschfaktoren aktivieren SopE und SopE2 die Rho GTPasen CDC42 und Rac1. GTP-geladenes CDC42 und Rac1 wiederum aktivieren das Aktinzytoskelett und stimulieren die Polymerisierung von Aktinfilamenten über den Arp2/3-Komplex an der Invasionsstelle. Das Pathogen wird dadurch in ein membranumhülltes Vesikel, die sogenannte Salmonella-containing Vakuole (SCV), aufgenommen. Die SCV stellt eine protektive, replikative, intrazelluläre Nische des Pathogens dar und wird permanent durch verschiedene Virulenzfaktoren moduliert.
Im Allgemeinen führt die Aktivierung von Mustererkennungsrezeptoren und Danger-Rezeptoren also zu einer zellulären Stressantwort und Entzündungsreaktion, wodurch es zur Bekämpfung der Infektion kommt. Inflammatorische Signalwege werden meist über den zentralen Transkriptionsfaktor NF-κB (nuclear factor 'kappa-light-chain-enhancer' of activated B-cells) vermittelt. NF-κB bewirkt die Induktion von proinflammatorischen Effektoren und Stressgenen. Zellautonome Immunität wird zusätzlich durch antibakterielle Autophagie ermöglicht, wobei Salmonella selektiv über das lysosomale System abgebaut werden. Das bakterielle Typ-III-Sekretionssystem verursacht an einigen wenigen SCVs Membranschäden, sodass Salmonella das Wirtszytosol penetrieren. Zytosolische Bakterien werden dabei spezifisch ubiquitiniert. Dies erlaubt die Erkennung durch die Autophagie-Maschinerie.
In der vorliegenden Arbeit wurde die zellautonome Immunität von Epithelzellen während einer akuten Salmonella Infektion durch quantitative Proteomik untersucht...
Lysosomes are major degradative organelles that contain enzymes capable of breaking down proteins, nucleic acids, carbohydrates, and lipids. In the last decade, new discoveries have traced also important roles for lysosomes as signalling hubs, affecting metabolism, autophagy and pathogenic infections. Therefore, maintenance of a healthy lysosome population is of utmost importance to the cell to respond to both stress conditions and also homeostatic signalling. For example, for minor perturbations to the lysosomal membrane, the cell activates repair processes which seal membrane nicks. For more extensive damage, autophagy is activated to remove damaged organelles from the cell. on the other hand, during pathogen invasion host cells have also evolved mechanisms to hijack the endolysosomal pathway to facilitate their own growth and replication in host cells.
The first part of the thesis work focuses on a lysosomal regeneration program which is activated under conditions where the entire lysosomal pool of the cell is damaged. Upon extensive membrane damage induced by the lysosomotropic drug LLOMe, the cell activates a regeneration pathway which helps in the formation of new functional lysosomes by recycling damaged membranes. I have identified the molecules important for this novel pathway of lysosomal regeneration and showed how the protein TBC1D15 orchestrates this process to regenerate functional organelles from completely damaged membrane masses in the first 2 hours following lysosomal membrane damage. This process resembles the process of auto- lysosomal reformation (ALR)- involving the formation of lysosomal tubules which are extended along microtubules and cleaved in a dynamin2 dependent manner to form proto-lysosomes which develop into fully functional mature lysosomes. These lysosomal tubules are closely associated with ATG8 positive autophagosomal membranes and require ATG8 proteins to bind to the lysophagy receptor LIMP2 on damaged membranes. This process is physiologically important under conditions of crystal nephropathy where calcium oxalate crystals induce damage to lysosomal membranes in nephrons in kidney disease.
The second part of the thesis shows how the endolysosomal system of the cell is hijacked by the bacteriaLegionella pneumophila. During Legionella infection the formation of conventional ATG8 positive autophagosomes are blocked due to the protease activity of the bacterial effector protein RavZ which cleaves lipidated ATG8 proteins from autophagosomal membranes. The SidE effectors of Legionella modify STX17 and SNAP29 by the process of non-canonical ubiquitination called phosphoribose-linked serine ubiquitination (PR-Ub). These proteins are essential for the formation of the autophagosomal SNARE complex which is used for fusion of the autophagosome with the lysosome. Upon Legionella infection, PR-UB of STX17 aids in formation of autophagosome-like replication vacuoles. ThesevacuolesdonotfusewiththelysosomebecauseSNAP29isalsoPR-Ubmodified. PR-UbofSTX17 and SNAP29 sterically blocks the formation of the autophagosomal-SNARE complex thereby preventing fusion of the autophagosome with the lysosome. As a result, Legionella can replicate in autophagosome- like vacuoles which do not undergo lysosomal degradation. In absence of PR-Ub modified STX17, bacterial replication is compromised when measured by bacterial replication assays in lung epithelial (A549) cells.
Taken together, this thesis highlights two important aspects of the autophagy-lysosomal system- how it responds to extensive membrane damage and its importance in Legionella pneumophila infection. Extensive damage to lysosomal membranes triggers a rapid regeneration process to partially restore lysosomal function before the effects of TFEB dependent lysosomal biogenesis becomes apparent. On the other hand, Legionella pneumophila infection segregates the lysosomes from the rest of the endo-lysosomal system by blocking autophagosome-lysosome fusion. Though lysosomes remain active, they are incapable of degrading pathogens since pathogen containing vacuoles do not fuse with the lysosome.
This thesis is concerned with protein structures determined by nuclear magnetic resonance (NMR), and the text focuses on their analysis in terms of accuracy, gauged by the correspondence between the structural model and the experimental data it was calculated from, and in terms of precision, i.e. the degree of uncertainty of the atomic positions. Additionally, two protein structure calculation projects are described...
Das Hauptziel dieser Dissertation lag in der Verbesserung einzelner Schritte im Prozess der automatischen Proteinstrukturbestimmung mittels Kernmagnetischer Resonanz (NMR). Dieser Prozess besteht aus einer Reihe von sequenziellen Schritten, welche zum Teil bereits erfolgreich automatisiert wurden. CYANA ist ein Programmpaket, welches routinemäßig zur automatischen Zuordnung der chemischen Verschiebungen, der Nuclear Overhauser Enhancement (NOE) Signalen und der Strukturrechnung von Proteinen verwendet wird. Einer der Schritte, der noch nicht erfolgreich automatisiert wurde, stellt die Signalidentifizierung von NMR Spektren dar. Dieser Schritt ist besonders wichtig, da Listen von NMR-Signalen Grundlage aller Folgeschritte sind. Fehler in den Signallisten pflanzen sich in allen Folgeschritten der Datenauswertung fort und können am Ende in falschen Strukturen resultieren. Daher war ein Ziel dieser Arbeit, einen robusten und verlässlichen Algorithmus zur Signalidentifizierung von NMR Spektren in CYANA zu implementieren. Dieser Algorithmus sollte mit dem in FLYA implementierten Ansatz zur automatischen Resonanzzuordnung, der automatischen NOE-Zuordnung und der Strukturrechnung mit CYANA kombiniert werden. Der in CYANA implementierte CYPICK Algorithmus ahmt den von Hand durchgeführten Ansatz nach. Bei der manuellen Methode schaut sich der Wissenschaftler zweidimensionale Konturliniendarstellungen der NMR Spektren an und entscheidet anhand verschiedener Geomtrie- und Ähnlichkeitskriterien, ob es sich um ein Signal des Proteins oder um einen Artefakt handelt. Proteinsignale sind ähnlich zu konzentrischen Ellipsen und erfüllen bestimmte geometrische Kriterien, wie zum Beispiel ungefähr kreisförmiges Aussehen nach entsprechender Skalierung der spektralen Achsen und gänzlich konvexe Formen, die Artefakte nicht aufzeigen. CYPICK bewertet die Konturlinien lokaler Extrema nach diesen Bedingungen und entscheidet anhand dieser, ob es sich um ein echtes Signal handelt oder nicht. Das zweite Ziel dieser Arbeit war es ein Maß zur Quantifizierung der Information von strukturellen NMR Distanzeinschränkungen zu entwickeln. Der sogenannte Informationsgehalt (I) ist vergleichbar mit der Auflösung in der Röntgenkristallographie. Ein weiteres Projekt dieser Dissertation beschäftigte sich mit der strukturbasierten Medikamentenentwicklung (SBDD). SBDD wird meist von der Röntgenkristallographie durchgeführt. NMR hat jedoch einige Vorteile gegenüber der Röntgenkristallographie, welche interessant für SBDD sind. Daher wurden Strategien entwickelt, die NMR für SBDD zugänglicher machen sollen.
Das Steroid-Hormon 17ß-Estradiol ist maßgeblich an der Entstehung und Entwicklung von Brustkrebs beteiligt. Die intrazelluläre Verfügbarkeit des aktiven Estrogens, 17ß-Estradiol, wird durch die 17ßHydroxysteroiddehydrogenase (17ßHSDl) reguliert, die die NADPH-abhängige Reduktion von Estron zu Estradiol katalysiert. Damit stellt die 17ßHSD1 einen interessanten Ansatzpunkt für die Entwicklung neuer Inhibitoren im Hinblick auf potente Wirkstoffe gegen Brustkrebs dar. Die 17ß-Hydroxysteroiddehydrogenase 2 bevorzugt hingegen die oxidative Aktivität und wandelt die biologisch aktiven Hydroxysteroide wie Estradiol in ihre inaktiven Ketoformen um. Ein möglicher Inhibitor der 17ß-HSD1 sollte demnach die Funktion der 17ß-HSD2 nicht beeinträchtigen. Im Rahmen dieser Arbeit wurden Strategien und Methoden entwickelt, die 17ßHSD1 durch heterologe Expression erstmals in E. coli darzustellen. Durch NMR-Spektroskopie in Kombination mit Docking konnten detaillierte Aussagen über die Bindungsepitope der untersuchten Liganden gemacht werden. Diese Informationen sind für eine gerichtete Optimierung von Leitstrukturen von großer Bedeutung.
Zusammenfassung Die Alzheimersche Krankheit (AD) ist mit 60% die am häufigsten auftretende Art der Demenz. Weltweit sind ca. 24 Mio. Menschen von der neurodegenerativen Krankheit betroffen, welche sich durch den Verlust der kognitiven Fähigkeiten auszeichnet. Es gibt zwei Ausprägungen der Demenz, zum einen die sporadische Verlaufsform, die bei Menschen in einem Alter ab 65 Jahren auftritt und zum anderen die familiäre Alzheimersche Krankheit (FAD), die schon weitaus jüngere Menschen betrifft und auf genetische Mutationen zurück zu führen ist. Beide Formen der Demenz zeigen den gleichen neuropathologische Phänotyp, der zur Ausbildung von extrazellulären Plaques und intrazellulären Neurofibrillen führt. Durch die Entstehung der Plaques und der Neurofibrillen werden die Verbindungen zwischen den einzelnen Neuronen verringert und die Neuronen sterben ab. Für das Auftreten der FAD sind Mutationen in den Genen des Amyloid Vorläufer Proteins (APP, Substrat) sowie der Aspartatprotease Einheit des γ-Sekretase Komplexes, Presenilin 1 (PS1) oder Presenilin 2 (PS2), verantwortlich. Die γ-Sekretase ist ein membranständiger Komplex bestehend aus den vier Untereinheiten PS1 oder PS2, Nicastrin (Nct), Aph-1 und Pen-2. Um ausreichende Informationen über den γ-Sekretase Komplex bezüglich seiner Interaktionsflächen, seines Katalysemechanismus und seiner Substraterkennung zu erhalten, wäre es hilfreich seine 3 Dimensionale Struktur aufzuklären, wozu große Mengen der sauberen und homogenen Proteine benötigt werden. Die Herstellung von ausreichenden Proteinmengen stellt derzeit aber einen Engpass für die strukturelle und funktionelle Charakterisierung des γ-Sekretase Komplexes in-vitro dar. Alzheimer’s disease (AD) is the most common cause of dementia, which affects 24 million people worldwide. It is a neurodegenerative disorder, which occurs either in its most common form in people over 65 years or in the rare early-onset familial AD (FAD). Responsible for the autosomal dominant FAD are mutations in the genes encoding for the β-amyloid precursor protein (APP) and the two homologues integral membrane proteins Presenilin 1 (PS1) and Presenilin 2 (PS2). The two PSs are major but alternative components of the intramembrane aspartyl protease γ-secretase. Further components are the membrane proteins Nicastrin (Nct), Aph-1 and Pen-2. Production of sufficient amounts of protein samples is still the major bottleneck for the detailed functional and structural in-vitro characterization of the γ-secretase complex. Due to toxicity, stability and targeting problems, the overproduction of MPs in conventional in-vivo systems often has only limited success. Therefore, efficient expression protocols using the cell-free (CF) system were established in this work. After optimization, I was able to produce up to milligram amounts of the single proteins PS1 and PS2, the cleavage products PS1-NTF and PS1-CTF, and Pen-2. The in-vitro produced γ-secretase subunits were further characterized, concerning their purity, secondary fold, thermal stability and homogeneity. Highest purities with over 90% after affinity chromatography could be achieved for PS1-CTF and Pen-2. Reconstitution of PS1, PS1-NTF, PS1-CTF and Pen-2 into E. coli liposomes results in a homogeneously distribution, which gives evidence for a structural folding. This was confirmed by CD spectroscopy of PS1-CTF and Pen-2. The thermal stability of Pen-2 shows a transition at 68°C, whereas PS1-CTF is stable up to 95°C. Both proteins show in addition homogeneous elution profiles investigated by analytical SEC and exhibit a monomeric (Pen-2) or dimeric (PS1-CTF) character analyzed by blue native PAGE. Different methods were performed to get evidence about the assembly of the complex, like pull-down experiments, immunoprecipitation, co-expression of radioactive labeled subunits and titration assays by liquid-state NMR. First hints for an interaction of the CF synthesized proteins could be observed by co-expression. Supplemental, Pen-2 and CTF could be purified in sufficient amounts and to apparent homogeneity that allow structural approaches by X-ray crystallography and liquid-state NMR spectroscopy. First conditions for protein crystals were achieved for Pen-2 and structural investigations of PS1-CTF by liquid-state NMR could be performed after optimization of the expression-, purification- and detergent conditions.
Biochemical and functional analysis of the ubiquitin binding properties of the NF-κB regulator NEMO
(2012)
Posttranslationale Modifikationen regulieren wesentliche Eigenschaften von Proteinen, wie z. B. Lokalisation, Konformation, Aktivität, Stabilität und Interaktionsfähigkeit. Eine besondere Form der Proteinmodifikation ist die Ubiquitylierung, bei der das kleine Protein Ubiquitin mit seinem C-Terminus kovalent an ein Substratprotein gebunden wird.
Die am besten untersuchte Funktion der Ubiquitylierung ist die Markierung eines Substrates für den Abbau durch das Proteasom. In den letzten Jahren wurde jedoch entdeckt, dass Ubiquitylierung in vielen Bereichen der Zelle eine wichtige Rolle spielt. Dazu gehören der Transport von Vesikeln, die Reparatur von DNA-Schäden und zelluläre Signalübertragung. Ubiquitin kann verschieden-artige Ketten bilden, indem ein Ubiquitin an eines der sieben Lysine (K6, K11, K27, K29, K33, K48, K63) oder den N-Terminus eines anderen gebunden wird. Diese unterschiedlichen Kettentypen regulieren verschiedene Prozesse. Z. B. dienen K48-verknüpfte Ubiquitinketten als Signal für den proteasomalen Abbau, wohingegen über K63 verknüpfte Ketten hauptsächlich eine Rolle bei Signalübertragungen spielen.
Die meisten Funktionen die durch Ubiquitylierung reguliert werden, werden durch Ubiquitinrezeptoren vermittelt, die eine Ubiquitinbindedomäne (UBD) besitzen. Manche UBDs binden selektiv nur einen Ubiquitinkettentyp und sind somit in der Lage gezielt Prozesse regulieren zu können, indem sie nur durch diesen speziellen Kettentyp aktiviert werden.
Das Protein NEMO ist ein Ubiquitinrezeptor, dessen UBD UBAN selektiv bestimmte Ubiquitinketten bindet. NEMO spielt eine zentrale Rolle bei der Aktivierung der Transkriptionsfaktorfamilie NF-κB, indem es den IKK-Kinasekomplex reguliert. Dieser Kinasekomplex sorgt durch die Phosphorylierung des NF-κB-Inhibitors IκBα für dessen proteasomalen Abbau, wodurch schließlich NF-κB aktiviert wird. Die NF-κB-Aktivierung kann u. a. durch den TNF-Rezeptor (TNFR) induziert werden. Am aktivierten TNFR werden viele Proteine durch verschiedene Ubiquitinketten modifiziert. Bisher wurde angenommen, dass die spezifische Bindung von NEMO an K63-verknüpfte Ubiquitinketten ausschlaggebend für die Aktivierung von IKK ist. Jedoch spielen lineare Ubiquitinketten, die über den N-Terminus verknüpft sind, auch eine wichtige Rolle bei der Aktivierung von NF-κB und die UBAN von NEMO hat eine sehr hohe Affinität zu linearen Ubiquitinketten.
Um die genauen Vorgänge zu verstehen, die zur Aktivierung von NF-κB am TNFR führen, ist es nötig, zu analysieren, welche Proteine mit welchen Ubiquitinketten modifiziert werden und welche Ubiquitinrezeptoren daran binden.
In dieser Studie sollte detailliert untersucht werden, mit welchen Ubiquitin-ketten NEMO bevorzugt interagiert. Dazu wurden in vitro-Bindungsstudien mit bakteriell aufgereinigtem NEMO und verschiedenen Ubiquitinketten durchgeführt. Des Weiteren sollte geprüft werden, wie die Bindung von NEMO an bestimmte Ubiquitinketten die Aktivierung von NF-κB reguliert.
Dabei ergab sich, dass sowohl NEMO in voller Länge, als auch die UBAN, bevorzugt mit linearen Ubiquitinketten interagieren, wohingegen die Interaktion von NEMO mit anderen Ubiquitinketten relativ schwach ist. Ausgehend von einer Kristallstruktur eines Komplexes aus der NEMO-UBAN und linearem di-Ubiquitin, wurden NEMO-Mutanten generiert, die seletkiv die Bindung von NEMO an lineare Ubiquitinketten verhindern, während die schwache Bindung von NEMO an längere K63-verknüpfte Ketten erhalten blieb. Um die Relevanz der Interaktion von NEMO mit linearen Ubiquitinketten für die Aktivierung von NF κB zu überprüfen, wurden diese NEMO-Mutanten dann verwendet um Zellen die kein NEMO exprimieren zu rekonstituieren. Nach Stimulation dieser Zellen mit TNFα wurde NF-κB kaum aktiviert, womit gezeigt werden konnte, dass NEMO gezielt an lineare Ubiquitinketten binden muss, um NF-κB zu aktivieren. Zusätzlich zu seiner Rolle bei der Aktivierung von NF-κB ist NEMO ein wichtiger Inhibitor der durch den TNFR induzierten Apoptose. In dieser Studie wurde gezeigt, dass diese Apoptoseinhibierung abhängig von der Bindung von NEMO an lineare Ubiquitinketten ist, da die Zellen die NEMO-Mutanten exprimierten, die keine linearen Ketten binden können, durch Apoptose starben, währen Wildtyp-Zellen überlebten.
Zusammenfassend konnte in dieser Studie gezeigt werden, dass NEMO bevorzugt und mit vergleichsweise hoher Affinität an lineare Ubiquitinketten bindet und dass diese spezifische Bindung wichtig für die Inhibierung von TNFR-induzierter Apoptose sowie für die Aktivierung von NF-κB ist.
G-protein coupled receptors (GPCRs) are the key players in signal perception and transduction and one of the currently most important class of drug targets. An example of high pharmacological relevance is the human endothelin (ET) system comprising two rhodopsin-like GPCRs, the endothelin A (ETA) and the endothelin B (ETB) receptor. Both receptors are major modulators in cardiovascular regulation and show striking diversities in biological responses affecting vasoconstriction and blood pressure regulation as well as many other physiological processes. Numerous disorders are associated with ET dysfunction and ET antagonism is considered an efficient treatment of diseases like heart failure, hypertension, diabetes, artherosclerosis and even cancer. This study exemplifies strategies and approaches for the preparative scale synthesis of GPCRs in individual cell-free (CF) systems based on E. coli, a newly emerging and promising technique for the production of even very difficult membrane proteins. The preparation of high quality samples in sufficient amounts is still a major bottleneck for the structural determination of the ET receptors. Heterologous overexpression has been a challenge now for decades but extensive studies with conventional cell-based systems had only limited success. A central milestone of this study was the development of efficient preparative scale expression protocols of the ETA receptor in qualities sufficient for structural analysis by using individual CF systems. Newly designed optimization strategies, the implementation of a variety of CF expression modes and the development of specific quality control assays finally resulted in the production of several milligrams of ETA receptor per one millilitre of reaction mixture. The versatility of CF expression was extensively used to modulate GPCR sample quality by modification of the solubilization environment with detergents and lipids in a variety of combinations at different stages of the production process. Downstream processing procedures of CF synthesized GPCRs were systematically optimized and sample properties were analysed with respect to homogeneity, protein stability and receptor ligand binding competence. Evaluation was accomplished by an array of complementary and specifically modified techniques. Depending on its hydrophobic environment, CF production of the ETA receptor resulted in non-aggregated, monodisperse forms with sufficient long-term stability and high degrees of secondary structure thermostability. The obtained results document the CF production of the ETA receptor in two different modes as an example of a class A GPCR in ligand-binding competent and non-aggregated form in quantities sufficient for structural approaches. The presented strategy could serve as basic guideline for the production of related receptors in similar systems.
The universal biological energy currency adenosine triphosphate (ATP) is synthesized by the F1Fo-ATP synthase in most living organisms. The overall structure and function of F-type ATPases is conserved in the different organisms. The F1Fo-ATP synthase consist of two domains; the soluble F1 complex has the subunit stoichiometry α3β3γδε and the membrane embedded Fo complex consists of subunits ab2c10-15 in its simplest form found in bacteria. F1 and Fo both function as reversible rotary motors that are connected by a central stalk (γε) and a peripheral stalk (b2δ).
For ATP synthesis, the electrochemical energy formed by a proton or sodium ion gradient is required. The ion translocation across the Fo subcomplex induces torque in the motor part of the enzyme (cnγε), which causes conformational changes in the α3β3 domain leading to ATP synthesis from ADP and inorganic phosphate (Pi) catalyzed in the β-subunits. ATP hydrolysis causes a reverse torque in the Fo subcomplex triggering uphill ion translocation from cytoplasm to periplasm, and the enzyme functions as an ion pump.
The ATP synthesis mechanism is well understood, since several high-resolution structures of F1 are available. In contrast, the ion translocation mechanism across the membrane, mediated by the Fo subcomplex, is not understood in its structural detail.
Subunit a and the c-ring form an ion pathway, but subunit b is needed to form an active ion translocation pathway in both H+- and Na+-dependent systems. Several high-resolution structures of c-rings have provided insights in the ion translocation mechanism. The different ion translocation models based on biochemical, biophysical and structural analysis are in agreement in the fact that ions are translocated through a periplasmic ion access pathway in subunit a to the middle of the membrane and there to the binding site of a c-subunit. After almost a whole rotation of the c-ring the ion returns into the a-c interface, where it can be released to the cytoplasm. In the different models the cytoplasmic access pathway has been proposed to be located in subunit a, at the a-c interface or within the c-ring. The driving force of torque generation has been proposed to be the pH gradient or membrane potential. Several biochemical studies show that a conserved arginine in helix four of subunit a (R226 in Ilyobacter tartaricus or R210 in Escherichia coli)plays a critical role in the ion translocation. The arginine has been proposed to function as an electrostatic separator between the cytoplasmic and periplasmic pathways and as a mediator of the ion exchange into the c-ring ion-binding site.
Structural data of a related enzyme (V1Vo-ATPase from Thermus thermophilus) has provided insight into the helical arrangement of the ion translocating subunits I and Lring (related to subunit a and the c-ring). These structures indicated a small interface between subunit I and the L-ring, and two four-helix bundles in the N-terminal domain of subunit I were proposed to build the periplasmic and cytoplasmic ion pathways. To comprehend the ion-translocation and torque generation mechanism in F1Fo-ATP synthase, structural data of an intact a-c complex is needed.
The goal of this work was to obtain structural data of subunit a, most preferably in a complex with the c-ring or additionally with subunit b. Therefore, a new purification procedure for the I. tartaricus Fo-subcomplex, heterologously expressed in E. coli cells, was established. The purified Fo was characterized biochemically and by Laserinduced liquid bead ion desorption mass spectrometry (LILBID-MS). These analyses showed that pure and completely assembled Fo containing all its subunits in the correct stoichiometry (ab2c11) was obtained. The purified Fo complex was stable at 4°C for several months and at room temperature in the presence of lipids for several weeks. A lipid analysis was performed by thin-layer chromatography (TLC) to investigate the qualitative lipid composition of I. tartaricus whole lipid extract and various I. tartaricus F1Fo isolates. The whole lipid extract contained PC, PG and PE lipids and probably cardiolipin. PC, PG and PE lipids were bound to wild type I. tartaricus F1Fo, whereas recombinant I. tartaricus F1Fo did not have any bound lipids, but was able to bind the synthetic lipids POPC and POPG if they were provided during the purification.
For subsequent structural studies the purified Fo was subjected to two-dimensional (2D) crystallization trials. Vesicles and sheets tightly packed with protein and crystals with a rare plane group for I. tartaricus c11 (p121) were obtained. The c-ring was visible in the CCD images, and immunogold-labeling revealed the presence of the His-tagged a-subunit in the reconstituted vesicles. Furthermore, atomic force microscopy (AFM) imaging showed protein densities next to the c-rings, which protruded less from the membrane (0.4±0.1 nm) than the c-ring (0.7±0.1 nm). These protein densities presumably belonged to subunit a.
Cryo-electronmicroscopy (cryo-EM) was used to collect data of the p121 crystals and a merged projection density map was calculated to 7.0 Å resolution. The unit cell of the crystals (81 × 252 Å) contained two asymmetric units with three c-rings in each and next to the c11-rings new prominent densities were visible. In each extra density up to 7 transmembrane helices were visible, belonging to the stator subunit a and/or subunit b. To elucidate whether there are conserved elements in the three extra densities non-crystallographic averaging was applied using a single-particle approach.
Six possible arrangements for the c-rings and the extra densities were identified and used for the averaging. The extra densities were enhanced only in one of the possible arrangements. The average showed a four-helix bundle and a fifth helix in close proximity to the c-ring. Two more helices were present in each position but their position was ambivalent. The data obtained in this work provides the first insight in the helical arrangement in the a-c interface of F1Fo-ATP synthase.
Bispezifische transmembrane Antikörperfragmente zur Inhibierung von ErbB-Wachstumsfaktor-Rezeptoren
(2014)
Der epidermale Wachstumsfaktor-Rezeptor (EGFR) und das ErbB2 Molekül sind Mitglieder der ErbB-Rezeptortyrosinkinase-Familie. Die Bindung von Peptidliganden an die extrazelluläre Domäne (ECD) von EGFR führt zu einer Konformationsänderung, die den Dimerisierungs-kompetenten Zustand des Rezeptors stabilisiert und eine Homodimerisierung oder Heterodimerisierung mit anderen ErbB-Rezeptoren erlaubt. ErbB2 liegt dagegen ohne Ligandenbindung dauerhaft in einer Dimerisierungskompetenten Konformation vor. Die Rezeptordimerisierung stimuliert die intrazelluläre Kinaseaktivität, was zu einer Autophosphorylierung distinkter Tyrosine im C-terminalen Schwanz der Rezeptoren führt. Diese Phosphotyrosine dienen als Bindungsstellen unterschiedlicher intrazellulärer Substrate und Adaptorproteine, die Zellwachstums-, Migrations- und Überlebens-fördernde Signalkaskaden auslösen. Eine Über- oder Fehlfunktion dieser Rezeptoren wurde in vielen Karzinomen epithelialen Ursprungs sowie in Glioblastomen beschrieben und mit einem aggressiven Krankheitsverlauf in Verbindung gebracht.
Der therapeutische Antikörper Cetuximab inhibiert das Tumorwachstum, indem er an die ECD von EGFR bindet und dabei die Ligandenbindung und Rezeptoraktivierung unterbindet. Dieselben Eigenschaften weist das single chain fragment variable (scFv) 225 auf, das die gleiche Antigenbindungsdomäne besitzt. Ein weiteres scFv-Antikörperfragment, scFv(30), wurde in vorangegangenen Arbeiten der Gruppe aus einer scFv-Bibliothek isoliert und bindet als zytoplasmatisch stabil exprimierbares Molekül an die intrazelluläre Domäne (ICD) des EGFR.
Im ersten Teil dieser Arbeit wurde das bislang unbekannte Epitop des scFv(30) Antikörperfragments mittels Peptid-Spotting Experimenten bestimmt. Die Bindungsstelle des scFv(30) Proteins wurde dabei am C-terminalen Ende der EGFR Sequenz lokalisiert und umfasst die Aminosäuresequenz GIFKGSTAE (AS 1161-1169 des reifen EGFR Proteins).
Die Expression von Antikörperfragmenten als sogenannte Intrabodies in Tumorzellen stellt einen wirkungsvollen Ansatz zur selektiven Interferenz mit wichtigen physiologischen und pathophysiologischen Prozessen dar. Im zweiten Teil der vorgelegten Arbeit wurde das EGFR-ECD-spezifische Antikörperfragment scFv(225) über eine Transmembrandomäne und eine flexible Gelenkregion mit dem EGFR-ICD-spezifischen scFv(30) Molekül zu einem neuartigen bispezifischen Antikörper verbunden. Die konstitutive Expression dieses 225.TM.30 Intrabodies und der monospezifischen Variante 225.TM nach lentiviraler Transduktion von EGFR-überexprimierenden MDA MB468 und A431 Tumorzellen resultierte in einer substanziellen Reduktion der EGFR-Oberflächenexpression und einer Blockierung der Liganden-induzierten EGFR-Autophosphorylierung, begleitet von einer deutlichen Inhibition des Zellwachstums. Eine weitere Analyse der 225.TM.30-induzierten molekularen Prozesse in diesen Tumorzellen im Vergleich zu den beiden monospezifischen Varianten 225.TM und TM.30 erfolgte mittels eines Tetracyclin-induzierbaren Expressionssystems. Dazu wurden A431, MDA-MB468 und EGFR-negative MDA-MB453 Zellen zunächst mit retroviralen Vektorpartikeln transduziert, die für den optimierten reversen Tetracyclin-kontrollierten Transaktivator (M2) kodieren. Anschließend erfolgte die Tansduktion mit retroviralen transmembranen Antikörperkonstrukten, kontrolliert von einem Tetracyclin-induzierbaren Promoter (T6). Die Doxycyclin (Dox)-induzierte Expression von 225.TM.30 und 225.TM bestätigte die im konstitutiven Expressionssystem beobachteten Ergebnisse. TM.30-exprimierende Zellen zeigten dagegen keinen Unterschied in der Oberflächenexpression oder Aktivierbarkeit von EGFR zu parentalen Zellen, wiesen aber dennoch eine deutliche Inhibition des Wachstums auf. Konfokale Laserscanning Mikroskopie Studien zeigten eine Co-Lokalisation von 225.TM und EGFR hauptsächlich an der Zelloberfläche, während 225.TM.30 und TM.30 im endoplasmatischen Retikulum detektiert wurden und EGFR in diesem Kompartiment festhielten. Die TM.30/EGFR-Komplexe im ER könnten eine ER-Stress-Antwort auslösen und damit das reduzierte Wachstum TM.30-exprimierender Zellen erklären. Tatsächlich wurden in MDA MB468/M2/iTM.30 und A431/M2/iTM.30 Zellen erhöhte Proteindisulfidisomerase (PDI) und teilweise GRP78/BiP Proteinmengen detektiert, die auf eine ER-Stress-Antwort hindeuten. Das bispezifische 225.TM.30 Molekül vereinte die Eigenschaften der monospezifischen Antikörpervarianten. Es hielt wie TM.30 Anteile des EGFR im ER zurück und war wie 225.TM in der Lage, die EGFR-Oberflächenexpression zu reduzieren und die EGFR-Autophosphorylierung zu inhibieren.
Die Expression der drei transmembranen Antikörper in EGFR-negativen MDA-MB453/M2 Zellen hatte dagegen keinen Einfluss auf das Wachstum dieser Zellen, was die EGFR-Spezifität der vorgestellten Moleküle unterstreicht.
Im letzten Teil der vorgelegten Arbeit wurde die scFv(225) Domäne in 225.TM.30 gegen das ErbB2-ECD-spezifische scFv(FRP5) Molekül ausgetauscht, und somit ein ErbB2-ECD- und EGFR-ICD-spezifischer Intrabody generiert (5.TM.30). Nach der Dox-induzierten Expression des 5.TM.30 Moleküls in EGFR- und/oder ErbB2-exprimierenden Tumorzellen wurde die Funktionalität beider Bindungsdomänen verifiziert. Die 5.TM.30 Expression resultierte dabei in ErbB2-positiven Tumorzellen in einer verringerten Oberflächen- und Gesamtexpression von ErbB2 und in EGFR-positiven Zellen in einer Reduktion der EGFR-Gesamtproteinmenge. Dies lässt auf eine erhöhte, 5.TM.30-induzierte Degradation der beiden Rezeptoren schließen. Die Expression des 5.TM.30 Proteins führte zudem zu einer Inhibition des Wachstums EGFR- und/oder ErbB2-positiver Zellen. Weiterhin wurde auch in 5.TM.30-exprimierenden MDA-MB468/M2 Zellen, wie für 225.TM.30 und TM.30 beschrieben, eine Co-Lokalisation des transmembranen Antikörperfragments mit EGFR im ER gezeigt.
Die in dieser Arbeit vorgestellten Ergebnisse weisen erstmals die Funktionalität von membranverankerten mono- und bispezifischen Antikörpermolekülen als Intrabodies nach, und zeigen ihr Potenzial zur gerichteten Interferenz mit der Wachstumsfaktor-abhängigen Signaltransduktion. Durch den Austausch der extra- und intrazellulären Antikörperdomänen könnte diese Strategie ebenso zur Analyse oder Blockade weiterer Signalmoleküle und Signalkomplexe eingesetzt werden.
Small molecule drug discovery is strongly supported by biophysical data. In the reach of this thesis, cell free protein expression was used to produce human target proteins for ligand binding assays using Surface Plasmon Resonance spectroscopy (SPR). In the second step the binding and interaction characteristics of small molecules and fragments were analyzed using Nuclear Magnetic Resonance spectroscopy (NMR).
The first target protein was the human acid sensing channel 1 (ASIC1a). ASIC1a was expressed in a cell free expression system based on E.coli lysate. To optimize the expression, several parameters including fusion tags, ion concentrations and different hydrophobic environments were tested.
The adaption of the folding environment for ASIC1a needed more optimization, because it is a very challenging target to express in an in vitro system. Three different expression modes were employed to find a suitable folding environment.
SPR binding studies with ASIC1a were performed with chicken ASIC1a expressed in insect cells. The immobilization of cASIC1a and the used buffer conditions were tested using Psalmotoxin 1, a naturally occurring peptide venom which binds strong to the trimeric form of ASIC1a. Compound characterization experiments were performed with a variety of different ligands including amiloride, a general blocker of the whole ENaC protein family. None of the used ligands showed titration curves that would match a simple 1:1 binding model. The experiments either show no binding signal or signal that could be interpreted as unspecific binding. Even amiloride that should be binding the protein shows no signals that fit a simple binding model.
Another target protein that was investigated is the soluble prolyl cis/trans isomerase Cyclophilin D (or peptidyl prolyl isomerase F – PPIF). This protein is involved in the regulation of the mitochondrial permeability transition pore and therefore a potential drug target to treat neurodegenerative diseases. Small molecule binding was tested with CypD using SPR. Following the kinetic analysis of small molecule ligands, the binding position of different binding fragments was analyzed. These fragments originated from a SPR based fragment screen and gave no co-crystal structures with CypD. Therefore NMR was used to investigate the binding position of these fragments. An analysis of the chemical shift perturbations upon ligand addition revealed that the NMR analysis was in line with the results gathered by x-ray crystallography. The fragments with unknown binding position however, all bind to a specific patch slightly outside the binding pocket.
The ligand CL1 showed a special behavior in the NMR experiments. Upon addition to CypD, it produced large shifts on many signals of the protein, accompanied by a severe line broadening. The shift perturbations were so numerous and large that the spectrum had to be reassigned in complex with the ligand. Triple selective labeling was applied to allow a fast and nearly complete signal assignment. The possibility to use highly sophisticated labeling schemes, is one of the advantages of cell free protein expression. After the assignment of the complex spectrum, the chemical shift perturbations were analyzed and quantified. The residues showing the strongest CSPs are also identified in the crystal structure to be involved in the binding of CL1, giving a consistent picture. The numerous and large shift perturbations, produced by CL1 led to the assumption, that the ligand induces a conformational change in CypD, which is not represented in the co-crystal structure. This conformational change was characterized by a NMR based structure determination. CypD apo yielded a defined bundle, whose folded regions overlap well with the corresponding crystal structure.
For the calculation of the CypD-CL1 complex structure, the sidechain resonances were assigned using an automated assignment approach with the software FLYA. The calculation of the CypD-CL1 complex structure did not result in a defined bundle. While parts of the protein converge in a well folded state, the region around the active site shows no defined folding. Careful analysis of the structure calculation suggests that the problems during structure calculation did not originate from an incorrect resonance assignment, but rather from a lack of NOE crosspeaks. This might be due to a broadening of the corresponding NOE crosspeaks or the coexistence of many different conformations. This leads to the conclusion, that the protein conformation is not defined by the NMR data and could be in a dynamic interchange between multiple structures.
This hypothesis is supported by other observations. The line broadening of the signals in the complex is pronounced in the area around the active site and the substrate binding pocket, hinting to a connection between catalytic activity and protein dynamics. In addition many NMR signals are sensitive to changes in the measurement field strength and the temperature. This field dependent signal splitting suggests dynamic conformational changes in the protein between at least two different conformations on a millisecond timescale.
The current working model is that CL1 binds to CypD and induces the catalytic cycle and the connected conformational changes in CypD. As a result the proline like moiety in CL1 is constantly switching between the cis and the trans conformation. Due to the high affinity of CL1, the inhibitor does not leave the binding pocket after successful catalysis, but stays bound in the pocket stimulating further catalytic cycles. These findings as well as the working model are well in line with data published for Cyclophilin A, another member of the cyclophilin family, thereby supporting the model.
Alzheimer’s disease (AD), which was first reported more than a century ago by Alhzeimer, is one of the commonest forms of dementia which affects >30 million people globally (>8 million in Europe). The origin and pathogenesis of AD is poorly understood and there is no cure available for the disease. AD is characterized by the accumulation of senile plaques composed of amyloid beta peptides (Ab 37-43) which is formed by the gamma secretase (GS) complex by cleaving amyloid precursor protein. Therefore GS can be an attractive drug target. Since GS processes several other substrates like Notch, CD44 and Cadherins, nonspecific inhibition of GS has many side effects. Due to the lack of crystal structure of GS, which is attributed to the extreme difficulties in purifying it, molecular modeling can be useful to understand its architecture. So far only low resolution cryoEM structures of the complex has been solved which only provides a rough structure of the complex at low 12-15 A resolution Furthermore the activity of GS in vitro can be achieved by means of cell-free (CF) expression.
GS comprises catalytic subunits namely presenilins and supporting elements containing Pen-2, Aph-1 and Nicastrin. The origin of AD is hidden in the regulated intramembrnae proteolysis (RIP) which is involved in various physiological processes and also in leukemia. So far growth factors, cytokines, receptors, viral proteins, cell adhesion proteins, signal peptides and GS has been shown to undergo RIP. During RIP, the target proteins undergo extracellular shredding and intramembrane proteolysis.
This thesis is based on molecular modeling, molecular dynamics (MD) simulations, cell-free (CF) expression, mass spectrometry, NMR, crystallization, activity assay etc of the components of GS complex and G-protein coupled receptors (GPCRs).
First I validated the NMR structure of PS1 CTF in detergent micelles and lipid bilayers using coarse-grained MD simulations using MARTINI forcefield implemented in Gromacs. CTF was simulated in DPC micelles, DPPC and DLPC lipid bilayer. Starting from random configuration of detergent and lipids, micelle and lipid bilyer were formed respectively in presence of CTF and it was oriented properly to the micelle and bilyer during the simulation. Around DPC molecules formed micelle around CTF in agreement of the experimental results in which 80-85 DPC molecules are required to form micelles. The structure obtained in DPC was similar to that of NMR structure but differed in bilayer simulations showed the possibility of substrate docking in the conserved PAL motif. Simulations of CTF in implicit membrane (IMM1) in CHAMM yielded similar structure to that from coarse grained MD.
I performed cell-free expression optimization, crystallization and NMR spectroscopy of Pen-2 in various detergent micelles. Additionally Pen-2 was modeled by a combination of rosetta membrane ab-initio method, HHPred distant homology modeling and incorporating NMR constraints. The models were validated by all atom and coarse grained MD simulations both in detergent micelles and POPC/DPPC lipid bilayers using MARTINI forcefield.
GS operon consisting of all four subunits was co-expressed in CF and purified. The presence of of GS subunits after pull-down with Aph-1 was determined by western blotting (Pen-2) and mass spectrometry (Presenilin-1 and Aph-1). I also studied interactions of especially PS1 CTF, APP and NTF by docking and MD.
I also made models and interfaces of Pen-2 with PS1 NTF and checked their stability by MD simulations and compared with experimental results. The goal is to model the interfaces between GS subunits using molecular modeling approaches based on available experimental data like cross-linking, mutations and NMR structure of C-terminal fragment of PS1 and transmembrane part of APP. The obtained interfaces of GS subunits may explain its catalysis mechanism which can be exploited for novel lead design. Due to lack of crystal/NMR structure of the GS subunits except the PS1 CTF, it is not possible to predict the effect of mutations in terms of APP cleavage. So I also developed a sequence based approach based on machine learning using support vector machine to predict the effect of PS1 CTF L383 mutations in terms of Aβ40/Aβ42 ratio with 88% accuracy. Mutational data derived from the Molgen database of Presenilin 1 mutations was using for training.
GPCRs (also called 7TM receptors) form a large superfamily of membrane proteins, which can be activated by small molecules, lipids, hormones, peptides, light, pain, taste and smell etc. Although 50% of the drugs in market target GPCRs , only few are targeted therapeutically. Such wide range of targets is due to involvement of GPCRs in signaling pathways related to many diseases i.e. dementia (like Alzheimer's disease), metabolic (like diabetes) including endocrinological disorders, immunological including viral infections, cardiovascular, inflammatory, senses disorders, pain and cancer.
Cannabinoid and adrenergic receptors belong to the class A (similar to rhodopsin) GPCRs. Docking of agonists and antagonists to CB1 and CB2 cannabinoid receptors revealed the importance of a centrally located rotamer toggle switch, and its possible role in the mechanism of agonist/antagonist recognition. The switch is composed of two residues, F3.36 and W6.48, located on opposite transmembrane helices TM3 and TM6 in the central part of the membranous domain of cannabinoid receptors. The CB1 and CB2 receptor models were constructed based on the adenosine A2A receptor template. The two best scored conformations of each receptor were used for the docking procedure. In all poses (ligand-receptor conformations) characterized by the lowest ligand-receptor intermolecular energy and free energy of binding the ligand type matched the state of the rotamer toggle switch: antagonists maintained an inactive state of the switch, whereas agonists changed it. In case of agonists of β2AR, the (R,R) and (S,S) stereoisomers of fenoterol, the molecular dynamics simulations provided evidence of different binding modes while preserving the same average position of ligands in the binding site. The (S,S) isomer was much more labile in the binding site and only one stable hydrogen bond was created. Such dynamical binding modes may also be valid for ligands of cannabinoid receptors because of the hydrophobic nature of their ligand-receptor interactions. However, only very long molecular dynamics simulations could verify the validity of such binding modes and how they affect the process of activation.
Human N-formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) involved in many physiological processes, including host defense against bacterial infection and resolving inflammation. The three human FPRs (FPR1, FPR2 and FPR3) share significant sequence homology and perform their action via coupling to Gi protein. Activation of FPRs induces a variety of responses, which are dependent on the agonist, cell type, receptor subtype, and also species involved. FPRs are expressed mainly by phagocytic leukocytes. Together, these receptors bind a large number of structurally diverse groups of agonistic ligands, including N-formyl and nonformyl peptides of different composition, that chemoattract and activate phagocytes. For example, N-formyl-Met-Leu-Phe (fMLF), an FPR1 agonist, activates human phagocyte inflammatory responses, such as intracellular calcium mobilization, production of cytokines, generation of reactive oxygen species, and chemotaxis. This ligand can efficiently activate the major bactericidal neutrophil functions and it was one of the first characterized bacterial chemotactic peptides. Whereas fMLF is by far the most frequently used chemotactic peptide in studies of neutrophil functions, atomistic descriptions for fMLF-FPR1 binding mode are still scarce mainly because of the absence of a crystal structure of this receptor. Elucidating the binding modes may contribute to designing novel and more efficient non-peptide FPR1 drug candidates. Molecular modeling of FPR1, on the other hand, can provide an efficient way to reveal details of ligand binding and activation of the receptor. However, recent modelings of FPRs were confined only to bovine rhodopsin as a template.
To locate specific ligand-receptor interactions based on a more appropriate template than rhodopsin we generated the homology models of FPR1 using the crystal structure of the chemokine receptor CXCR4, which shares over 30% sequence identity with FPR1 and is located in the same γ branch of phylogenetic tree of GPCRs (rhodopsin is located in α branch). Docking and model refinement procedures were pursued afterward. Finally, 40 ns full-atom MD simulations were conducted for the Apo form as well as for complexes of fMLF (agonist) and tBocMLF (antagonist) with FPR1 in the membrane. Based on locations of the N- and C-termini of the ligand the FPR1 extracellular pocket can be divided into two zones, namely, the anchor and activation regions. The formylated M1 residue of fMLF bound to the activation region led to a series of conformational changes of conserved residues. Internal water molecules participating in extended hydrogen bond networks were found to play a crucial role in transmitting the agonist-receptor interactions. A mechanism of initial steps of the activation concurrent with ligand binding is proposed.
I accurately predicted the structure and ligand binding pose of dopamine receptor 3 (RMSD to the crystal structure: 2.13 Å) and chemokine receptor 4 (CXCR4, RMSD to the crystal structure 3.21 Å) in GPCR-Dock 2010 competition. The homology model of the dopamine receptor 3 was 8 th best overall in the competition.
The human endothelin receptors, ETA and ETB, are two members of the G-protein coupled receptors family (GPCRs) and they are key players in cardiovascular regulation. The characterization of their functionality in vitro has been limited by the possibility to obtain high quality samples using conventional expression systems. The Cell-Free expression system is an alternative technique for the production of membrane protein as well as GPCRs and can overcome some of the limitations that are commonly encountered using an in vivo approach. Cell-Free expression protocols for the two receptors ETA and ETB have been optimized by implementing post- and co-translational association to lipid bilayers. The efficiency of the reconstitution or association to liposomes and nanodiscs has systematically been studied and the ligand binding properties of the two receptors have been analyzed using a set of different complementary techniques. In several different conditions a high affinity binding of the peptide ligand ET-1 to both endothelin receptors could be obtained and the highest activity values were detected in sample prepared using a co-translational approach in presence of nanodiscs. Furthermore, the characteristic differential binding pattern of selected agonists and antagonists to the two receptors was confirmed. In samples obtained from several Cell-Free expression conditions, two intrinsic properties of the functionally folded ETB receptor, such as the proteolytic processing based on conformational recognition as well as the formation of SDS-resistant complexes with the peptide ligand ET-1, were detected. ETA and ETB are able to induce in vivo the activation of hetrotrimeric G proteins upon stimulation with an agonist, leading to the dissociation of the heterotrimeric complex and the exchange of GDP to GTP in the Galpha subunit. The Cell-Free expression system was chosen for the production of two G alpha subunit, Galpha s and Galpha q. Soluble expression of the two proteins was achieved and the production of active Galpha s was confirmed using fluorescent as well as radioactive assays. In conclusion, the obtained results document a new process for the production of ligand binding competent endothelin receptors, as well as Galpha proteins, using a Cell-Free expression system. The combination of this expression system and the nanodiscs technology appears to be a promising tool for the further characterization of membrane proteins as well as GPCRs.
G-protein coupled receptors (GPCRs) are a predominant class of cell-surface receptors in eukaryotic life. They are responsible for the perception of a broad range of ligands and involved in a multitude of physiological functions. GPCRs are therefore of crucial interest for biological and pharmaceutical research. Molecular analysis and functional characterisation of GPCRs is frequently hampered by challenges in efficient large-scale production, non-destructive purification and long-term stability. Cell-free protein synthesis (CFPS) provides new production platforms for GPCRs by extracting the protein synthesis machinery of the cell in an open system that allows target-oriented modulations of the synthesis process and direct access to the nascent polypeptide chain. CFPS is fast, reliable and highly adaptable. Unfortunately, highly productive cell-free synthesis of GPCRs is often opposed by low product quality. This thesis was aimed to adapt and improve some of the new possibilities for the cell-free production of GPCRs in high yield and quality for structural and pharmaceutical analysis. An E. coli based CFPS system was applied to synthesise various turkey and human Beta-adrenergic receptor (Beta1AR) derivatives as well as human Endothelin receptors type A and B (ETA and ETB) constructs. Both receptor families are important drug targets and pharmacologically addressed in the treatment of several cardiovascular diseases. CF-synthesis was mainly performed in presence of nanodiscs (ND), which are reconstituted high density lipoprotein particles forming discoidal bilayer patches with a diameter varyring from 6 to approx. 15 nm. The supplementation of ND in the CF-synthesis reaction caused the co-translational solubilisation of the freshly synthesised GPCRs. The fraction of the solubilised GPCR that was correctly folded was analysed by the competence to bind its ligand alprenolol or Endothelin-1, respectively. Both the solubilisation efficiency and the ability to fold in a ligand binding competent state was strongly affected by the lipid composition of the supplied ND. Best results were generally achieved with lipids having phosphoglycerol headgroups and unsaturated fatty acid chains with 18 carbon atoms. Furthermore, thermostabilisation by introduction of point mutations had a large positive impact on the folding efficiency of both Beta1AR and ETB receptor. Formation of a conserved disulphide bridge in the extracellular region was additionally found to be crucial for the function of the ETB receptor. Disulphide bridge formation could be enhanced by applying a glutathione-based redox system in the CFPS. Further improvements in the quality of ETB receptor could be made by the enrichment of heat-shock chaperones in the CF-reaction. Depending on the receptor type and DNA-template, roughly 10 – 30 nmol (350 – 1500 µg) of protein could be synthesised in 1 ml of CF-reaction mixture. After the applied optimisation steps, the fractions of correctly folded receptor could be improved by several orders of magnitude and were finally in between 35% for the thermostabilised turkey Beta1AR, 9% for the thermostabilised ETB receptor, 6.5% for the non-stabilised ETB receptor, 1 - 5% for non-stabilised turkey Beta1AR and for human Beta1AR isoforms and 0.1% for ETA receptor. Therefore, between 2 and 120 µg of GPCR could be synthesised in a ligand binding competent form, depending on the receptor and its modifications. Correctly folded turkey Beta1AR and ETB receptors were thermostable at 30°C and could be stored at 4°C for several weeks after purification. Yields of the thermostabilised turkey Beta1AR were sufficient to purify the receptor in a two-step process by ligand-binding chromatography to obtain pure and correctly folded receptor in the lipid bilayer of a ND. Furthermore, a lipid dependent ligand screen could be demonstrated with the turkey Beta1AR and significant alterations in binding affinities to currently in-use pharmaceuticals were found. The established protocols are therefore suitable and highly competetive for a variety of applications such as screening of GPCR ligands, analysis of lipid effects on GPCR function or for the systematical biochemical characterisation of GPCRs. Most promising for future approaches appears to address the suspected bottlenecks of intial insertion of the GPCR-polypeptide chain in the ND bilayer and the thermal stability of the receptors. Nevertheless, the estabilised protocols for the analysed targets in this thesis are already highly competitive to previously published production protocols either in cell-based or cell-free systems with regard to yield of functional protein, speediness and costs. Moreover, the direct accessibility and other general characteristics of cell-free synthesis open a large variety of possible applications and this work can therefore contribute to the molecular characterisation of this important receptor type and to the development of new pharmaceuticals.
Cell-free-synthesized voltage-gated proton channels: Approaches to the study of protein dynamics
(2018)
We often only realize how important health is when diseases manifest themselves through their symptoms and, ultimately, in a diagnosis. Over time, we suffer from many diseases starting with the first childhood disease to colds to gastrointestinal infections. Most diseases pass harmlessly and symptoms fade away. However, not all diseases are so harmless. Alzheimer’s disease, breast cancer, Parkinson’s disease, and colorectal cancer usually cause severe illness with high mortality rates. In pharmaceutical research, efforts are therefore being made to determine the molecular basis of them in order to provide patients with potential relief and, at best, healing. A special group of regulators, involved in the previously mentioned diseases, are voltage-gated proton channels. Thus, the understanding of their structure, function, and potential drug interaction is of great importance for humanity.
Voltage-gated proton channels are localized in the cell membrane. As their name indicates, they are controlled by voltage changes. Depolarization of the cell membrane induces conformational changes that open these channels allowing protons to pass through. Here, the transfer is based on a passive process driven by a concentration gradient between two individual compartments separated by the cell membrane. Voltage-gated proton channels are highly selective for protons and show a temperature- and pH-dependent gating behavior. However, little is known about their channeling mechanism. Previous experimental results are insufficient for understanding the key features of proton channeling.
In this thesis, for the first time, the cell-free production of voltage-sensing domains (VSD) of human voltage-gated proton channels (hHV1) and zebrafish voltage-sensing phosphatases (DrVSP) is described. Utilizing the cell free approach, parameters concerning protein stability, folding and labeling can be easily addressed. Furthermore, the provision of a membrane mimetic in form of detergent micelles, nanodiscs, or liposomes for co-translational incorporations of these membrane proteins is simple and efficient. Both VSDs were successfully produced up to 3 mg/ml. Furthermore, the cell-free synthesis enabled for the first time studies of lipid-dependent co-translational VSD insertions into nanodiscs and liposomes. Cell-free produced VSDs were shown to be active, and to exist mainly as dimers. In addition, also their activation was stated to be lipid-dependent, which has not been described so far. Solution-state NMR experiments were performed with fully and selectively labeled cell-free produced VSDs. With respect to the development of potential drug candidates, I could demonstrate the inhibition of the VSDs by 2-guanidinobenzimidazole (2GBI). Determined KD values were comparable to literature data for the human construct. For the first time, a low affinity for 2GBI of the zebrafish VSD could be described.
In future, the combination of a fast, easy and cheap cell-free production of fully or selectively labeled VSDs and their analysis by solution state NMR will enable structure determinations as well as inhibitor binding studies and protein dynamic investigations of those proteins. The results of these investigations will serve as a basis for example for the development of new drugs. In addition, a detailed description of the lipid-dependent activity might be helpful in controlling the function of voltage-gated proton channels in cancer cells and thereby reducing their growth or disturbing their cell homeostasis in general.
HDAC inhibitors (HDACI), a new class of anticancer agents, induce apoptosis in many cancer entities. JNJ-26481585 is a second generation class І HDACI that displays improved efficacy in preclinical studies compared to the established HDACI SAHA (Vorinostat). Therefore, this study aims at evaluating the effects of JNJ-26481585 on human rhabdomyosarcoma (RMS) and at identifying novel synergistic interactions of JNJ-26481585 or the more common HDACI SAHA with different anticancer drugs in RMS cells. Indeed, we show that JNJ-26481585 and SAHA significantly increase chemotherapeutic drug-induced apoptosis in embryonal and alveolar RMS cell lines, when used in combination with chemotherapeutic agents (i.e. doxorubicin, etoposide, vincristine, and cyclophosphamide) which are currently used in the clinic for the treatment of RMS.
We demonstrate that JNJ-26481585 as single agent and in combination with doxorubicin induces apoptosis, which is characterized by activation of the caspase cascade, PARP cleavage, and DNA fragmentation. Induction of caspase-dependent apoptotic cell death is confirmed by the use of the broad-range caspase inhibitor zVAD.fmk, which significantly decreases both JNJ-26481585-triggered and combination treatment-mediated DNA fragmentation, and in addition completely abrogates loss of cell viability. Importantly, JNJ-26481585 significantly inhibits tumor growth in vivo in two preclinical RMS models, i.e. the chicken chorioallantoic membrane (CAM) model and a xenograft mouse model, supporting the notion that JNJ-26481585 hampers tumor maintenance. Also, in combination with doxorubicin JNJ-26481585 significantly reduces tumor growth in in vivo experiments using the CAM model.
Mechanistically, we identify that JNJ-26481585-induced apoptosis is mediated via the intrinsic apoptotic pathway, since we observe increased loss of mitochondrial membrane potential and activation of the proapoptotic Bcl-2 family members Bax and Bak. Interestingly, we find that JNJ-26481585 triggers induction of Bim, Bmf, Puma, and Noxa on mRNA level as well as on protein level, pointing to an altered transcription of BH3-only proteins as important event for the Bax/Bak-mediated loss of mitochondrial membrane potential as well as mitochondrial apoptosis induction upon JNJ-26481585 treatment. JNJ-26481585-initiated activation of Bax and Bak is not prevented with the addition of zVAD.fmk, suggesting that JNJ-26481585 first disrupts the mitochondria and subsequently activates the caspase cascade. When JNJ-26481585 is used in combination with doxorubicin, we observe not only an increase of proapoptotic Bcl-2 proteins, but also a decrease in the level of the antiapoptotic mitochondrial proteins Bcl-2, Mcl-1, and Bcl-xL. This indicates that Bax, Bak, Bim, and Noxa are crucial for JNJ-26481585-induced as well as JNJ/Dox treatment-induced apoptosis, since RNAi mediated silencing of Bax, Bak, Bim, and Noxa significantly impedes DNA fragmentation upon those treatments.
Furthermore, ectopic overexpression of Bcl-2 profoundly impairs both JNJ-26481585 and combination treatment-mediated apoptosis, abrogates caspase cleavage, and reduces activation of Bax and Bak, underlining the hypothesis that JNJ-26481585 initially targets the mitochondria and then activates caspases.
With the more commonly used HDACI SAHA we confirm the results obtained with the HDACI JNJ-26481585, since combination treatment with SAHA and doxorubicin also induces intrinsic apoptosis, which can be significantly diminished by zVAD.fmk or ectopic overexpression of Bcl-2. Treatment with SAHA and doxorubicin also affects expression levels of pro- and antiapoptotic mitochondrial proteins, thus shifting the balance towards the proapoptotic mitochondrial machinery, resulting in Bax/Bak activation, caspase activation, and subsequently apoptosis.
Taken together, we provide evidence that the HDACIs JNJ-26481585 and SAHA are promising therapeutic agents for the treatment of RMS and that combination regimens with HDACIs represent an efficient strategy to prime RMS cells for chemotherapy-induced apoptosis. These findings have important implications for mitochondrial apoptosis-targeted therapies of RMS.
The focus of this research was to understand the molecular mechanism that lies behind the insertion of tail-anchored membrane proteins into the ER membrane of yeast cells. State-of-art instruments such as LILBID, and Cryo-EM, combined with the introduction of direct electron detectors, were used to analyze the proteins that capture tail-anchored proteins near the ER membrane and help their releases from a chaperone, an ATPase named Get3. Get3 escorts TA proteins to the ER membrane, where both Get3 and the TA proteins interact sequentially to Get3 membrane bound receptors Get1 and Get2. Get1 and Get2 are homologs of mammalian WRB and CAML.
The native host was used to separately produce Get1, Get2, and the Get2/Get1 single chain constructs. The studies showed that when Get1 is expressed alone, Get1 does not seems to be located in the ER membrane but rather in microbodies like shape organelles (or peroxisome). Interestingly, Get1 seems to be located in the ER membrane when it is linked to Get2 as single chain construct.
The localization study of Get2/Get1 fused to GFP shows from the fluorescence intensity that Get2/Get1.GFP has a tube-like morphology or membrane-enclosed sacs (cisterna), implying that Get2/Get1 is actually targeted to the ER membrane and is likely functional. In other words, Get1 and Get2 stabilize each other in the ER membrane.
The expression of Get2/Get1 was found to be already optimum when expressed as single chain construct because the fluorescence counts did not improve when additives such as DMSO or histidine were added. However, when Get1 and Get2 are expressed separately, additives improve their protein production yield. In 1 liter culture, Get1 yield is increased by about 3 mg and Get2 by 1.8 mg. This can be explained by the space that Get1 and Get2 should occupy within the ER membrane as they must coexist with other membrane components to maintain the homeostasis of the cell. Hence, if there were no gain for single chain construct expression, it meant that Get2/Get1 was already well expressed on its own in ER membrane and has reached its optimum expression without the help of additives. The Get2/Get1 overexpression is more stable, tolerated and less toxic for the cells to express it at a high level.
DDM has proved to be the best detergent from the detergents tested to solubilize Get1, Get2, and Get2/Get1.
Thereafter, Get1, Get2 (data not shown), and Get2/Get1 were successfully purified in DDM micelles.
Furthermore, for the first time using LILBID, the actual study has shown that Get1 and Get2 are predominantly a heterotetramer (2xGet1 and 2xGet2) but higher oligomerization may exist as well.
Get3 binds to Get1 in a biphasic way with a specific strong binding of an affinity of 57 nM and the second of 740 nM nonspecific indicative of heterogeneity within the interaction between Get1 and Get3. This heterogeneity is caused by the presence of different conformation of either protein. However, in order to characterize a high-resolution structure model of a specific target one needs highly homogenous and identical molecules of the target protein or complex in solution. The homogeneity increases the chances of growing crystals during crystallography as the good homogeneity will likely generate a perfect packing of unit cells stack (also known as crystal lattice) in the three-dimensional spaces. The same truth goes for the single particles analysis Cryo-EM, especially for smaller complexes where having less or no conformation alterations of specific targets will enable the researcher to classify the particles in 2D and 3D, therefore improving the signal-to-noise-ratio that will ultimately lead to high-resolution structure determination.
Get1, Get2/Get1 and chimeric variants (tGet2/Get1, T4l.Get2/Get1, T4l.Get2.apocyte.Get1) were crystallized but none of the crystals could diffract due to heterogeneity.
This heterogeneity was not only occurring upon the binding of Get3 to its membrane receptors, but seems to be already present within the receptors themselves through possibly different conformation.
In this Ph.D. thesis, the heterogeneity of purified Get2 and Get1 as complex or individually in detergent is then, so far, the limiting factor for obtaining a high-resolution structure model of Get1 and Get2. As mentioned above, the heterogeneity observed was not due to the quality of the sample preparation but rather to the effect of different conformations that could have been native, or just because of the micelle used, as it was proven by the 3-D heterogeneity classification by Cryo-EM.
In general, crosslinking is one way to keep the integrity of protein complexes, however it appeared not to improve the sample quality when it was analyzed in micelles. Often the integrity of some membrane proteins is affected when they are solubilized and purified in detergents.
Finally, in this study, the structural map of Get2 and Get1 complex linked with chimeric protein T4 lysozyme and apocytochrome C b562RIL gene was obtained at 10 Å. However, this single chain construct has a density map corresponding to heterodimer species (one Get1 and Get2). Therefore, based on those data the tertiary structure of Get2/Get1 in micelle is poorly defined. It could be that the membrane extraction in DDM and the purification destabilizes the structure of the complex.
The multistep-processes leading to the formation of tumors have been extensively studied in the past decades, leading to the identification of “hallmarks of cancer”. They are characteristic changes in biological processes that discriminate tumor cells from healthy cells. Increasing knowledge on the molecular structures associated with tumorigenesis allowed their specific inhibition in targeted anti-cancer therapy. However, successful targeted anti-cancer therapy is only available for a limited subset of diseases, so the continuous investigation of tumorigenic mechanisms is required to tackle the immense diversity of neoplastic entities.
AVEN and FUSE binding protein 1 (FUBP1) display the ability to regulate apoptosis and cell cycle progression. Thus, the proteins are associated with hallmarks of cancer (resisting cell death and uncontrolled proliferation). Indeed, aberrant expression of AVEN and FUBP1 could be demonstrated in multiple cancers. In contrast, there is only little knowledge on the physiological function of AVEN and FUBP1. The lack of knowledge results in part from the embryonic lethality of the homozygous knockout of Aven and Fubp1 in mouse models, limiting the gain of information by analyzing these animals.
In this study, I generated conditional Aven and Fubp1 knockout mice to investigate their physiological function.
By analyzing reporter mice expressing β-galactosidase under the control of the endogenous Aven promoter, I identified Aven promoter activity to be both tissue- and cell type-specific and dependent on the developmental stage. Detecting apoptotic cell death by immunohistochemistry did not reveal increased apoptosis in Aven knockout mice, suggesting a functional role of AVEN besides apoptosis inhibition during embryogenesis.
Basing on the significant Aven promoter activity detected in the adult brain and in the mammary gland, I generated and characterized conditional Aven knockout mice with Aven deletion restricted to cells within the brain or the mammary gland. AVEN depletion in these tissues was not embryonic lethal and the affected tissues displayed a normal histology.
Since aberrant Aven expression had been associated with hematologic malignancies, I also analyzed mice with an Aven knockout in the hematopoietic system. Depletion of AVEN in the blood cells had no effect on hematopoietic stem and progenitor cell frequencies. Consequently, AVEN seems to be dispensable for the maintenance and differentiation of stem, progenitor and mature blood cells, at least as far as the expression of particular differentiation markers was concerned.
As loss of AVEN in the analyzed tissues did not affect the viability of mice and did not produce any other obvious phenotype, the exact role of AVEN that is essential for embryo survival remains to be identified.
To study the oncogenic potential of AVEN, I investigated the role of AVEN in a mouse model for breast carcinogenesis. While AVEN expression seemed to be increased in breast tumors, tumor onset and progression were not altered in mice with depleted AVEN expression in the mammary gland. Consistently, Aven knockout tumor cells were neither less proliferative nor more prone to undergo apoptosis than Aven wildtype tumor cells. Cell culture experiments demonstrated that AVEN expression is upregulated by estrogen. Knockdown of AVEN in the breast cancer cell line MCF-7 slightly increased UV irradiation-induced apoptosis and accelerated metabolism. So while AVEN does not promote development or progression of breast tumors, enhanced AVEN expression in ER+ breast cancers might contribute to chemotherapy resistance.
To study the physiological role of FUBP1, I generated a conditional Fubp1 knockout mouse model. While the insertion of loxP sites into the Fubp1 locus was occasionally embryonic lethal, some mice with a cell type-specific deletion of Fubp1 in hematopoietic cells or EPO receptor expressing cells were born alive. In these mice, frequencies of hematopoietic stem and progenitor cells as well as erythrocytes were unaltered. These results conflict with previous publications. However, compensating mechanisms might be responsible for the discrepancies between the observed phenotypes and reported FUBP1 function.
In cell culture studies, I could demonstrate that the previously reported upstream regulation of FUBP1 by TAL1 depended on an intact GATA motif in the FUBP1 promoter and that binding of GATA1 to the FUBP1 promoter increased during erythropoiesis.
To identify new FUBP1 target genes with relevance for erythropoiesis, I performed differential gene expression analysis in cells with wildtype and depleted FUBP1 expression. RNA-sequencing and PCR-arrays revealed only moderate differences in the expression of genes that are components of the EPO receptor signaling pathway as well as genes associated with apoptosis and proliferation of hematopoietic cells. By regulating the transcription of these genes, FUBP1 could contribute to efficient erythropoiesis.
Throughout their life cells of eukaryotic organisms can be confronted with a variety of proteotoxic stresses and in order to survive, corresponding resistance mechanisms had to evolve. Proteotoxic stresses can cause misfolding of proteins and accumulation of toxic protein aggregates. Failure to remove aggregates of misfolded proteins compromises cellular function and can ultimately cause cell death and disease. To deal with this challenge, cells utilize a complex network of protein quality control pathways, including chaperones, the ubiquitin-proteasome system and the autophagy system.
Another mechanism to cope with proteotoxic stresses is the stalling of translation initiation in order to save valuable resources and prevent faulty translation. Upon stress, intrinsically disordered RNA-binding proteins such as TIA-1 or G3BP1/2 are recruited to stalled preinitiation complexes and a network of multivalent interactions between RNAs and proteins is formed. These mRNP networks can merge with each other and phase separate into membraneless liquid-like structures called stress granules (SGs). Once stress is released, SGs are quickly resolved and translation continues. Yet, chronic stress or mutations of SG-associated proteins can cause persistent SGs, which can sequester misfolded proteins and have been linked to neurodegenerative diseases such as amyotrophic lateral sclerosis or frontotemporal dementia.
In mammalian cells, three isoforms of the small ubiquitin-related modifier (SUMO), SUMO1, SUMO2 and SUMO3 are covalently attached to lysine residues of target proteins. SUMO conjugation is catalyzed via an enzymatic cascade of an heteromeric E1 activating enzyme, the E2 conjugating enzyme Ubc9 and in some cases one of a limited number of E3 SUMO ligases. SUMOylation is a dynamic modification and can be reversed by SUMO isopeptidases, the best characterized of which belong to the SENP family. Cellular stresses such as heat or oxidative stress strongly induce SUMOylation resulting in increased numbers of poly-SUMOylation (formation of SUMO2/3 chains) on nuclear proteins.
The SUMO-targeted ubiquitin ligase (STUbL) RNF4 harbors four SUMO interaction motifs in its N-terminal domain. This feature allows RNF4 to specifically bind poly-SUMOylated proteins and catalyze their proteolytic or non-proteolytic ubiquitylation.
A variety of substrate proteins have been shown to undergo SUMO-primed ubiquitylation by RNF4 in response to stress or DNA damage. RNF4-mediated ubiquitylation is often a signal for proteolytic degradation of these substrates.
In this work we aimed by identify novel RNF4 targets, in heat-stressed cells in order to gain a wider understanding of the nuclear proteotoxic stress response. Analysis by mass spectrometry revealed that a large fraction of RNF4-interacting proteins in heatstressed cells are nuclear RNA-binding proteins, many of which shuttle outside the nucleus and associate with SGs upon stress. We validated, that nuclear RNA-binding proteins, such as TDP-43 and hnRNP M are indeed heat-induced targets of SUMOprimed ubiquitylation by RNF4.
These initial results led us to further investigate the links between the SUMO/RNF4-mediated, nuclear protein quality control and the dynamics of cytosolic heat- or arsenite-induced SGs. SUMO2/3 and RNF4 are mainly nuclear proteins and we confirmed that they do not associate with SGs. Yet, we could demonstrate that depletion of SUMO2/3, the E3 SUMO ligase PML or RNF4 as well as chemical inhibition of SUMOylation strongly delayed SG clearance upon stress release, indicating that a functional STUbL pathway is essential for the timely clearance of SGs.
Next, we investigated how stress-induced poly-SUMOylation is regulated. Our data shows that SENP levels and activities are reduced in response to heat and arsenite stress, which allows the buildup of poly-SUMO chains on nuclear proteins. Limitation of poly-SUMOylation by overexpression of the SUMO chain-specific isopeptidases SENP6 and SENP7 induced SG formation. In contrast, poly-SUMO-priming by chemical depletion of SENP6 with the drug hinokiflavone drastically limited SG formation upon stress treatment. These results indicate a clear role of chain-specific SENPs in the regulation of stress-induced poly-SUMOylation and SG dynamics.
Last, we investigated whether the STUbL pathway could affect the phase separation of FUSP525 (an ALS-linked mutant of the SG-associated protein FUS) and observed that perturbations of the STUbL pathway lead to an increased phase separation of FUSP525L.
Thus, our work connects the SUMO/RNF4 protein quality control mechanism to the dynamics of SGs supporting the hypothesis that release of proteotoxic stress in the nucleus facilitates the clearance of cytosolic SGs. Thereby, we discovered a previously unknown link between the nuclear and cytosolic axis of proteotoxic stress response.
Die chromosomale Translokation t(4;11) ist mit einer aggressiven pro-B ALL im Kleinkindesalter assoziiert und stellt eine der häufigsten genetischen Veränderungen des MLL Gens dar. Bei bis zu 40 % der untersuchten Translokationen des MLL Gens wurde das AF4 Gen als Translokationspartner identifiziert. Durch Arbeiten in unserer Arbeitsgruppe konnte in Focus Formation Experimenten das wachstumstrans-formierende Potenzial sowohl des Wildtyp AF4 Proteins, als auch des bei der Translokation entstehenden AF4•MLL Fusionsproteins, nachgewiesen werden. Es kann somit als gesichert angesehen werden, daß es sich bei dem Wildtyp-AF4 Protein um ein Proto-Onkoprotein und bei dem AF4•MLL Fusionsprotein um ein Onkoprotein handelt. Der für beide Proteine identische Bereich beschränkt sich auf die ersten 360 Aminosäuren des AF4 Proteins, was der Hypothese führte, daß der N-Terminale Bereich des AF4 Proteins (AF4•N) für das beobachtete onkogene Potential in murinen embryonalen Fibroblasten verantwortlich ist. Ein mit dem AF4•N Protein durchgeführter Hefe-2-Hybrid Screen identifizierte die beiden E3-Ligasen SIAH1 und SIAH2 als Bindungspartner. Hierbei handelt es sich um Tumorsupressor- Proteine, die durch Ubiquitinylierung von Zielproteinen diese dem proteasomalen Abbau zuführen. Unter normalen physiologischen Bedingungen unterliegt das AF4 Protein einem raschen Abbau am Proteasom. Dies ist für das AF4•MLL Fusionsprotein nur noch eingeschränkt möglich, da es wie für das Wildtyp-MLL beobachetet proteolytisch gespalten wird, mit sich selbst dimerisiert und dann nicht mehr über das Proteasom abgebaut werden kann. Eine Bindung der beiden E3-Ligasen SIAH1 und SIAH2 konnte jedoch noch beobachtet werden, deshalb sollte die AF4 und SIAH Protein-Protein-Interaktion genauer untersucht werden. Hierzu wurden Hefe-2-Hybrid Experimente mit Deletionsmutanten durchgeführt, um die minimalen Kontakt-domänen zu identifiziert. Die Stärke der Interaktionen wurde durch ß-Galaktosidasetests ermittelt. Die identifizierte minimale AF4 Proteindomäne enthält das für die Erkennung durch die E3-Ligasen notwendige PxAxVxP Motiv und hat eine Länge von 25 Aminosäuren. Für die E3-Ligasen SIAH1 und SIAH2 konnte der für die Interaktion notwendige Kontaktbereich innerhalb der sogenannten Substrat-Bindungs-Domäne (SBD) lokalisiert werden. Interessanterweise ist nicht die große Furche des Dimerisierungsinterfaces der beiden SIAH Monomere der Kontaktbereich, sondern der proximale Zink-Finger Bereich. Die experimentell ermittelten Proteindomänen wurden in geeignete bakterielle Expressionssysteme kloniert und ihre in vitro Interaktion durch Pulldown-Experimente bestätigt. Die strukturelle Aufklärung der Kontaktdomäne erfolgte dann mit Hilfe der NMR-Fast-Mapping Methode. Mit dieser kombinatorischen Methode wurden die an der AF4 Bindung beteiligten Aminosäuren des SIAH Proteins durch Änderung ihrer chemischen Verschiebung im [15N,1H] HSQC-Spektrum nach Titration mit steigenden AF4 Konzentrationen identifiziert. Aus den erhaltenen Daten und anhand der bekannten SIAH Röntgenstruktur konnte ein Modell für die Bindung des AF4 Proteins an die E3-Ligase SIAH1 erstellt werden. Über die Funktion des Proto-Onkoproteins AF4 ist bis dato wenig bekannt. Es gibt Hinweise, daß alle Vertreter der ALF Proteinfamilie über transkriptionsaktivierende Eigenschaften verfügen. Da posttranslationale Modifikationen von Proteinen, wie z.B. Sumoylierung, häufig zur Regulation von Transkriptionsfaktoren beobachtet werden, wurden Untersuchungen auf posttranslationale Modifikationen des AF4 Proteins durchgeführt. Hierzu wurde durch Mutation der E3-Ligase Erkennungssequenz PxAxVxP eine stabilisierte AF4 Mutante hergestellt. Durch Immunopräzipitations Experimente nach Transfektion in 293T Zellen konnte sowohl die Sumoylierung, als auch Tyrosin Phosphorylierungen des AF4 Proteins nachgewiesen werden.